Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Unilever plc (UL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Unilever plc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $281.44 (market cap $39.89B), while Unilever plc trades at $61.67 (market cap $130.72B). The key difference: Unilever plc is far larger — about 3.3× Alnylam Pharmaceuticals, Inc.'s market cap, and Unilever plc pays a 3.69% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | UL | |
|---|---|---|
Market Cap | $39.89B | $130.72B |
Sector | Health | Consumer Staples |
52-Week High | $491.22 | $74.59 |
52-Week Low | $278.09 | $55.05 |
Enterprise Value | $38.15B | $156.17B |
Dividend Yield | — | 3.69% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Unilever (UL) trades at $61.72, up 1.2% with a bullish technical signal despite recent earnings misses. The company maintains strong profitability with 18.75% net margins and 53.32% ROE, though revenue declined to $60.76B in 2024. Recent developments include a transformative food business deal with McCormick and a $270M innovation center investment, positioning for future growth amid current headwinds.
UL presents a mixed outlook with strong brand power and cash flow generation offset by recent earnings disappointments and competitive pressures. The stock appears fairly valued at 20.93 P/E, with analyst consensus divided between growth potential from strategic initiatives and concerns about execution risks in a challenging consumer environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Unilever plc
Unilever is a diversified personal product (42% of 2021 sales by value), home care (20%), and packaged food (38%) company. Its brands include Knorr soups and sauces, Hellmann's mayonnaise, Lipton teas, Axe and Dove skin products, and the TRESemme haircare brand. The firm has been acquisitive in recent years
Read more on UL →
